Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

• Status: Active, not recruiting
• Trial end date: 2025-12-01

Summary

RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known whether suppression of ovarian function plus either tamoxifen or exemestane is more effective than tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer.

• Phase: Phase 3

Details

• Lead Sponsor: International Breast Cancer Study Group
• Collaborators: Breast International Group; Cancer and Leukemia Group B; National Cancer Institute (NCI); NCIC Clinical Trials Group; North Central Cancer Treatment Group; NSABP Foundation Inc; Southwest Oncology Group
• Treatments: Exemestane; Hormones; Tamoxifen; Triptorelin Pamoate; Tryptophan